Cargando…

Second generation androgen receptor antagonists and challenges in prostate cancer treatment

Prostate cancer is a hormone-dependent malignancy, whose onset and progression are closely related to the activity of the androgen receptor (AR) signaling pathway. Due to this critical role of AR signaling in driving prostate cancer, therapy targeting the AR pathway has been the mainstay strategy fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yanhua, Zhou, Qianqian, Hankey, William, Fang, Xiaosheng, Yuan, Fuwen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304354/ https://www.ncbi.nlm.nih.gov/pubmed/35864113 http://dx.doi.org/10.1038/s41419-022-05084-1

Ejemplares similares

Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer
por: Rajaram, Pravien, et al.
Publicado: (2020)

Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer
por: Kregel, Steven, et al.
Publicado: (2016)

Response to Androgens and Androgen Receptor Antagonists in the Presence of Cytokines in Prostate Cancer
por: Culig, Zoran
Publicado: (2021)

Castration-Resistant Prostate Cancer Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents: Opportunities and Challenges
por: Kita, Yuki, et al.
Publicado: (2018)

Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors
por: Saad, Fred, et al.
Publicado: (2021)

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
por: Hwang, Justin H., et al.
Publicado: (2019)

Second generation androgen receptor antagonist, TQB3720 abrogates prostate cancer growth via AR/GPX4 axis activated ferroptosis
por: Zhang, Zhongqing, et al.
Publicado: (2023)

Small Molecule Antagonists of the Nuclear Androgen Receptor for the Treatment of Castration-Resistant Prostate Cancer
por: Johnson, James K., et al.
Publicado: (2016)

Novel Treatment Strategy Using Second-Generation Androgen Receptor Inhibitors for Non-Metastatic Castration-Resistant Prostate Cancer
por: Chung, Doo Yong, et al.
Publicado: (2021)

Synthesis of Hydantoin Androgen Receptor Antagonists and Study on Their Antagonistic Activity
por: Ma, Longjun, et al.
Publicado: (2022)

Mechanisms of Androgen Receptor Agonist- and Antagonist-Mediated Cellular Senescence in Prostate Cancer
por: Kokal, Miriam, et al.
Publicado: (2020)

Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors
por: Wefel, Jeffrey S., et al.
Publicado: (2022)

Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models
por: Sugawara, Tatsuo, et al.
Publicado: (2019)

Influence of Androgen Receptor Antagonist MDV3100 Therapy on Rats With Benign Prostatic Hyperplasia
por: Yang, Minggen, et al.
Publicado: (2021)

Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis
por: Chen, Xiangyu, et al.
Publicado: (2023)

H3K9 methylation drives resistance to androgen receptor–antagonist therapy in prostate cancer
por: Baratchian, Mehdi, et al.
Publicado: (2022)

Antagonistic Functions of Androgen Receptor and NF-κB in Prostate Cancer—Experimental and Computational Analyses
por: Basílio, José, et al.
Publicado: (2022)

Cheminformatic Analysis and Machine Learning Modeling to Investigate Androgen Receptor Antagonists to Combat Prostate Cancer
por: Yu, Tianshi, et al.
Publicado: (2023)

An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer
por: Mohler, Michael L., et al.
Publicado: (2021)

Systems Pharmacology Modeling of Prostate‐Specific Antigen in Patients With Prostate Cancer Treated With an Androgen Receptor Antagonist and Down‐Regulator
por: Mistry, HB, et al.
Publicado: (2016)

Conformational dynamics of androgen receptors bound to agonists and antagonists
por: Gim, Hyo Jin, et al.
Publicado: (2021)

Advances of CRISPR-Cas13 system in COVID-19 diagnosis and treatment
por: Zhou, Qianqian, et al.
Publicado: (2022)

SUN-139 Luminescence-Based Drug Screen for Novel Androgen Receptor Antagonists for Prostate Cancer Therapy
por: Azur, Romie Angelo G, et al.
Publicado: (2020)

Androgen receptor agonist and antagonist reduce response of cytokine‐induced killer cells on prostate cancer cells
por: Pungsrinont, Thanakorn, et al.
Publicado: (2023)

Androgen receptor-mediated upregulation of quaking affects androgen receptor-related prostate cancer development and anti-androgen receptor therapy
por: Zhang, Keke, et al.
Publicado: (2018)

The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis
por: Zhang, Xianlu, et al.
Publicado: (2023)

Molecular determinants for enzalutamide-induced transcription in prostate cancer
por: Yuan, Fuwen, et al.
Publicado: (2019)

Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2017)

Simvastatin delays castration-resistant prostate cancer metastasis and androgen receptor antagonist resistance by regulating the expression of caveolin-1
por: Gao, Yingying, et al.
Publicado: (2019)

Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer
por: Han, G. Celine, et al.
Publicado: (2017)

Trends in the Use of Second-Generation Androgen Receptor Axis Inhibitors for Metastatic Hormone-Sensitive Prostate Cancer and Clinical Factors Predicting Biological Recurrence
por: Nakane, Keita, et al.
Publicado: (2023)

Biological and Clinical Significance of Androgens and Androgen Receptor in Prostate Cancer
por: Koochekpour, Shahriar
Publicado: (2014)

Role of androgen receptor splice variant 7 (AR-V7) in prostate cancer resistance to 2(nd) generation androgen receptor signaling inhibitors
por: Zhu, Yezi, et al.
Publicado: (2020)

Anticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors
por: Matsumoto, Takashi, et al.
Publicado: (2021)

Plasma Androgen Receptor in Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer
por: Lavaud, Pernelle, et al.
Publicado: (2020)

High Serum Alkaline Phosphatase Flare after First-Line Androgen Deprivation Therapy Predicts Poor Prognosis in Metastatic Prostate Cancer Patients Treated with Second-Generation Androgen Receptor Targeted Therapy
por: Kojima, Satoko, et al.
Publicado: (2021)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

The Androgen Receptor and VEGF: Mechanisms of Androgen-Regulated Angiogenesis in Prostate Cancer
por: Eisermann, Kurtis, et al.
Publicado: (2017)

Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope
por: Saranyutanon, Sirin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jj14rh8jp1rjh7trdqmc6samc0